Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCavendish Plc Regulatory News (CAV)

Share Price Information for Cavendish Plc (CAV)

Share Price is delayed by 15 minutes
Get Live Data
9.25    0.00 (0.00%)
Bid:
9.00
Ask:
9.50
Spread: 0.50 (5.556%)
Market Cap: £31.06m
CAV Live PriceLast checked at - London Stock Exchange

Intraday Cavendish Plc Share Chart

AGM Trading Statement

29 Sep 2023 07:00

RNS Number : 0410O
Cavendish Financial PLC
29 September 2023
 

29 September 2023

For immediate Release

 

Cavendish Financial plc ("Cavendish" or the "Group")

AGM Trading Statement

Cavendish Financial plc announces the following update ahead of its Annual General Meeting to be held today at 10.00 am:

On 8 September, finnCap Group plc and Cenkos Securities plc completed their merger to create Cavendish Financial plc, a full-service investment bank for ambitious growth companies.

The combined operation consists of just under 200 people operating from its headquarters in One Bartholomew Close, London and its Scottish office in Edinburgh. With 220 quoted clients, the Group has the largest retained client base amongst UK small and midcap investment banks, making it the go-to financial advisory firm for growth and investment companies. In addition to equity capital markets, Cavendish has expertise in M&A, debt advisory and private growth capital. The Group also has a strong global reach through its membership of Oaklins, an international advisory network.

 

Since the merger, the Group has relocated all of the London based Cenkos team to its London headquarters, launched the new operating brand Cavendish, centralised trading onto a single platform and made substantial progress with its IT integration. The integration of the operations team, a key part of delivering the synergies is also nearing completion. The Group will provide a further update on synergy realisation within its inaugural interim results expected to be announced in December.

 

Trading across the City has been quiet during the Summer, but since merger completion the Group has already announced a number of significant transactions which will close in the coming months including acting as sole adviser to Round Hill Royalty Fund Limited on its offer from Concord Cadence Limited, fundraisings for Haydale Graphene PLC and Shield Therapeutics plc and obtaining key regulatory clearances for the equity financing of Allergy Therapeutics by ZQ Capital and Southern Fox.

 

Contacts:

 

Cavendish Financial plc Tel: +44 (0)20 7220 0500

John Farrugia, co-CEO

Julian Morse, co-CEO

 

Grant Thorton UK LLP (Nominated Adviser to Cavendish) Tel: +44 (0)20 7383 5100

Philip Secrett/Samantha Harrison/Samuel Littler

Hudson Sandler (PR adviser to Cavendish)

Dan de Belder Tel: +44 (0) 7977 927142

Rebekah Chapman Tel: +44 (0) 7702 596674

 

 

About Cavendish 

Cavendish is a UK champion for ambitious growth and investment companies. The Group is trusted by public and private companies, operating across industry sectors, to deliver expert services in equity capital markets, M&A, debt advisory and growth capital.

 

Cavendish has offices in the City of London and Edinburgh and has a global reach through its membership of Oaklins. Cavendish Financial plc is quoted on AIM.

 

For more information on Cavendish, please visit www.cavendish.com

 

END

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGMUWROROUUKUAR
12
Date   Source Headline
10th Apr 20263:18 pmRNSDirectors Dealings
1st Apr 20267:00 amRNSFull Year Trading Update
26th Feb 20263:38 pmRNSHolding(s) in Company
3rd Feb 20262:30 pmRNSDirectors Dealings
18th Dec 20259:08 amRNSDirectors Dealings
15th Dec 20254:15 pmRNSDirector Dealing: Correction
11th Dec 20254:00 pmRNSDirector Dealing
2nd Dec 20257:00 amRNSBlock Admission Return and Total Voting Rights
21st Nov 20254:45 pmRNSHolding(s) in Company
30th Oct 20257:00 amRNS2026 Interim Results
16th Oct 202510:23 amRNSDirector Dealing
1st Oct 20257:00 amRNSHalf Year Trading Update: Profitable First Half
16th Sep 202511:00 amRNSResult of AGM
29th Aug 20257:00 amRNSTotal Voting Rights
18th Jul 202512:07 pmRNSPosting of Annual Report and Notice of AGM
8th Jul 20254:39 pmRNSHolding(s) in Company
3rd Jul 202511:13 amRNS-RInvestor Presentation via Investor Meet Company
26th Jun 20257:00 amRNS2025 Full Year Results
24th Jun 202510:32 amRNSResponse to press speculation
2nd Jun 20257:00 amRNSBlock Admission Return and Total Voting Rights
27th May 20259:02 amRNSHolding(s) in Company
1st May 20254:56 pmRNSTotal Voting Rights
1st May 20254:55 pmRNSDirectors Dealings
9th Apr 20254:02 pmRNSDirector Dealing
4th Apr 20257:00 amRNSFull Year Trading Update
4th Feb 202512:39 pmRNSCompany Name Change
31st Jan 202511:26 amRNSDirectors Dealings
31st Jan 202511:22 amRNSDirector Dealings
12th Dec 20242:56 pmRNSDirectors Dealings
2nd Dec 20247:00 amRNSBlock Admission Return and Total Voting Rights
13th Nov 20243:00 pmRNSDirectors Dealings
11th Nov 20247:00 amRNS2025 Interim Results
21st Oct 20242:37 pmRNSDirectors Dealings
7th Oct 20247:00 amRNSHalf Year Trading Update: Profitable First Half
24th Sep 20249:20 amRNSIntended Purchases of Shares by EBT
16th Sep 202412:42 pmRNSResult of AGM
16th Sep 20249:09 amRNSAGM Trading Statement
6th Sep 20247:00 amRNSRule 19.6(c) Confirmation
15th Aug 20243:00 pmRNSDirectors Dealings
1st Aug 20248:44 amRNSPosting of Annual Report and Notice of AGM
26th Jul 20247:00 amRNSTotal Voting Rights
18th Jul 20244:33 pmRNSDirector Dealings
15th Jul 20247:00 amRNS2024 Full Year Results
12th Jun 20242:41 pmRNSHolding(s) in Company
24th May 20247:00 amRNSDirectorate Change
22nd Apr 202410:00 amRNSDirectors Dealings
8th Apr 20247:01 amRNSHolding(s) in Company
8th Apr 20247:00 amRNSChange of Nominated Adviser
4th Apr 20247:00 amRNSTrading Update
28th Mar 20247:00 amRNSTotal Voting Rights
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.